PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to determine the effectiveness of PEG-Intron 1.5 ug/kg/wk plus REBETOL (ribavirin) 800-1400 mg/day in adults with chronic hepatitis C with moderate to severe liver fibrosis or cirrhosis who failed to respond to previous treatment with an alpha interferon in combination with ribavirin. Patients who do not respond to PEG-Intron plus REBETOL (ribavirin) will be enrolled in a long-term maintenance study to evaluate the effectiveness of PEG-Intron monotherapy versus no treatment for the prevention of disease progression (Protocols P02569 and P02570).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Interferon-alpha; Interferons; Peginterferon alfa-2b; Ribavirin

Criteria

Inclusion Criteria:

• Age at entry 18-65

• Positive for Hepatitis C

• Nonresponder to previous treatment (minimum of 3 months) with an alpha Interferon plus ribavirin

• Liver biopsy demonstrating moderate to severe fibrosis or cirrhosis

Exclusion Criteria:

• Any cause for the liver disease other than chronic hepatitis C

• History or presence of complications of cirrhosis

• Alcohol or illicit drug use or methadone treatment within the past 2 years

• Treatment for chronic hepatitis C within the previous 6 months

• Diseases or conditions that could interfere with the subject's participation in and completion of the study